Worldwide Clinical Trials’ Post

How can Worldwide support your metabolic dysfunction studies? Discover our full suite of MASH/MALD clinical development services in our fact sheet, from our core lab partnerships to global operational expertise: https://ow.ly/VyN550SwaQP

Want to hear about the latest cutting-edge initiatives reshaping oncology clinical trials? Discover FDA’s Project Optimus, novel study designs, and the impact of Bayesian models on drug development in our blog with Matt Cooper and james eamma: https://ow.ly/nU5150Sun6S

If you're in search for a bioanalytical partner to help advance your pre-clinical or clinical development program, look no further. Discover the bioanalytical difference at Worldwide! https://ow.ly/XziY50Sv484

Interested in the latest methods and solutions for running your oncology clinical trial? Make sure to check out james eamma’s presentation at Clinical Trials in Oncology East Coast next week, and stop by Booth 21 to speak to him about any questions you may have! https://ow.ly/k21H50Su0Jk

How do you stand out in rare neurological research? At Worldwide, we turn challenges into solutions, ensuring your trial’s success in both high- and low-competition environments by prioritizing patient voices and leveraging expert strategies. Find out how we do it in our blog: https://ow.ly/F6bs50St3xx

At Worldwide, we're dedicated to enhancing your drug development journey through our people, processes, and technologies in our bioanalytical lab and clinical pharmacology unit. This commitment is embodied in our continuous improvement initiative — WorldwideEdge. Learn more: https://ow.ly/rJ9f50SsTnS

Are you ready to make an impact in rare disease research? At Worldwide, we provide bespoke, patient-centered solutions for your rare disease program, from advocacy engagement to clinical assessment and technology. Discover more about our distinct rare disease methodology and expertise today: https://ow.ly/Jhmq50SsJkL

Radiopharmaceuticals are continuously evolving – work with a partner who specializes in this dynamic field. Discover Worldwide’s experience in radiopharmaceutical development from oncology to rare disease in our fact sheet: https://ow.ly/XYsQ50Sra23

In honor of Alzheimer's and Brain Awareness Month, Tom Babic reflects on the significant milestone passed in treating those affected by Alzheimer's disease: “While not a cure, lecanemab is the first FDA-approved drug in over 20 years to show an unequivocal positive effect in subjects with Alzheimer’s disease (AD). Made possible by the collective advancement in understanding of AD’s biology, diagnostics, and treatments, lecanemab presents an opportunity for patients at the Roskamp Institute and across the US to slow the progression of their devastating disease. It’s always rewarding to hear the direct impact of Worldwide’s work on patients and their families.” https://ow.ly/Ov7V50Sr9CU